Background. The human T lymphotropic virus (HTLV)-I or -II proviral load (VL) may be linked to viral pathogenesis, but prospective data on VL and disease outcomes are lacking.
viral DNA into the genome of the infected lymphocyte [1] [2] [3] [4] [5] . During chronic infection, there is little production of viral RNA or mature virions, and propagation of the infection is thought to occur via the clonal expansion of previously infected lymphocytes, with concomitant expansion of integrated HTLV proviral DNA [6] . The concentration of HTLV proviral DNA in vivo varies from as few as 10 to 1100,000 copies/10 6 peripheral blood mononuclear cells (PBMCs). HTLV-Iinfected individuals have been shown to have a mean proviral load (VL) of ∼0.7 log 10 copies/10 6 PBMCs higher than those of HTLV-II-infected individuals [7] . Stimuli to lymphocytic proliferation, such as parasitic infection or the treatment of concurrent HIV infection, may result in increased clonal expansion and higher VLs [8] [9] [10] . Previously, HTLV-I VL has been shown to be related to the risk of developing HTLV-associated myelopathy (HAM) [11, 12] and perhaps with the risk of developing adult T cell leukemia/lymphoma (ATL) [13, 14] . More recently, the VL has been shown to vary according to race and risk-factor history of the human host, which suggests that the infectious dose at the time of infection might determine the chronic VL [7] . Although the VL is likely to be an important determinant of viral pathogenesis, there are significant gaps in our knowledge about this measure. There is little information about the intrapersonal variability of the VL over time [15] and, if such variability exists, whether it is related to other characteristics of the host, such as demographic factors, the route of infection, or comorbid illness. Finally, it is unknown whether an increase, decrease, or other variation in VL precedes the onset of HTLVrelated disease and whether such variation may be used to predict the development of disease or clinical symptoms. As more investigators address the immunologic characteristics of HTLV infection, it is important that the description of the dynamics and determinants of VL proceeds in parallel.
We performed serial measurements of the VL in cryopreserved PBMCs from a well-characterized cohort of HTLV-Iand -II-infected individuals who have been monitored prospectively for 110 years, and we correlated VLs with demographic, risk-factor, and clinical outcome data.
SUBJECTS AND METHODS
Study design and population. The present study was a crosssectional and prospective analysis of blood samples obtained at the baseline and follow-up visits of the HTLV Outcomes Study (HOST) cohort, formerly known as the Retrovirus Epidemiology Donor Study HTLV cohort [7] . The formation of this cohort has been reported elsewhere [16] . Of the original 1340 members of the HOST cohort, subjects were chosen for baseline VL testing on the basis of adequate remaining specimen volume. Subjects with HAM or ATL and HTLV-positive sex partners of cohort members were excluded. The demographic and risk-factor associations of baseline HTLV VLs of this cohort have been reported elsewhere [16] . A subset of the subjects with baseline VL data was chosen to be further tested for variations in serial VL measurements. This substudy consisted of 30 HTLV-I-positive and 30 HTLV-II-positive subjects chosen to provide a representative sample of observed low (10th percentile), medium (50th percentile), and high (90th percentile) baseline VLs, again subject to adequate remaining specimen volume, from all 6 visits of the cohort subjects.
Real-time polymerase chain reaction (PCR). Frozen PBMCs from each time point were thawed and digested into lysates, and the VL was determined in triplicate for each sample using real-time quantitative PCR with SYBR green intercalation, as described elsewhere [17] . This assay had excellent amplification efficiency, as determined by diluted DNA standards included on each plate, had a lower limit of detection of a single copy per a reaction, and had good interassay reliability with an R 2 of 0.97 for HTLV-I-infected subjects and 0.94 for HTLV-IIinfected subjects. Serial samples from the same subject were included in the same testing batch, to minimize interassay effects on serial VLs. Cell input was determined by HLA-DQa quantification in the same aliquot [17] .
Statistical analysis. HTLV VLs are expressed as copies per 10 6 PBMCs by dividing the mean number of HTLV copies (3 replicate PCRs) by the mean number of HLA-DQa copies (3 replicate PCRs). For VLs that were undetectable, a value of 1 copy/10 6 PBMCs, the lower limit of detection of the VL assay, was assigned. For all analyses, these values were log-transformed to approximate the normal distribution.
Descriptive statistics for the cohort were determined using frequencies and proportions. Differences in mean log 10 VLs were assessed using 2-sample t tests. Baseline VLs were initially categorized into low, medium, and high VL groups, and these were compared with outcomes. Because associations with and the progression of VLs could differ by HTLV type, all models were stratified by HTLV-I versus HTLV-II status. Logistic-regression models were used to test the significance of associations between baseline VL and outcomes, with the exception of mortality, which was analyzed using Cox regression, to allow for age adjustment. Serial VLs were also initially categorized by each subject's individual mean, slope, and variance. Associations between these categories and demographic, risk-factor, and outcome variables were examined. To determine the statistical significance of such associations, repeated-measures analysis was performed using general estimating equations (GEE) models, with the assumption of an exchangeable correlation structure to adjust for log 10 VL measures clustering around subjects. All analyses were performed using Stata statistical software (version 8.2; StataCorp).
RESULTS
Characteristics of the study population and baseline VL. At baseline, VLs and epidemiologic data were available for 122 subjects with HTLV-I and 319 subjects with HTLV-II. HTLV-I-infected subjects (mean ‫ע‬ SE, log 10 copies/10 6 3.31 ‫ע‬ 0.12 PBMCs) had a significantly higher mean log 10 VL than did HTLV-II-infected subjects (mean ‫ע‬ SE, log 10 cop-2.61 ‫ע‬ 0.09 ies/10 6 PBMCs; ), as reported elsewhere [7] . Subjects P ! .0001 for whom serial VL data were available were chosen from among all subjects who completed the sixth biannual visit after a median of 10.4 years of follow-up, and demographic information remained similar to that of subjects who provided only baseline data (table 1) [7] . As before, the majority of subjects were middle-aged and female, and there was a good representation of blacks in the population. In the HTLV-I-infected group, 10% of subjects were Asian but none were Hispanic; in the HTLV-II-infected group, 23% of subjects were Hispanic NOTE. For demographics of the baseline VL group, see reference [7] . IDU, injection drug user; PBMCs, peripheral blood mononuclear cells.
but none were Asian. However, the group for whom serial VL data were available tended to have higher income levels than did the group for whom only baseline VL data were available. HTLV-I-infected subjects (mean ‫ע‬ SE, log 10 cop-3.28 ‫ע‬ 0.24 ies/10 6 PBMCs) had a higher mean log 10 VL than did HTLV-II-infected subjects (mean ‫ע‬ SE, log 10 copies/10 6 2.82 ‫ע‬ 0.31 PBMCs), although the difference was not statistically significant in the subgroup with serial VL data ( ). P p .25 Baseline VL and disease outcomes. In the larger group for whom baseline VL data were available, we tested the association between VL and a variety of 15 health outcomes (arthritis, asthma, bladder infection, bladder or kidney infection, bronchitis, cancer, diabetes, genital herpes, hypertension, kidney infection, lymphadenopathy, patellar hyperreflexia, pneumonia, thyroid disease, and urinary symptoms) and death. No statistically significant associations were found at the sig-P р .05 nificance level (data not shown). Adjustment for baseline age, allogenic versus autologous donor status, sex, and race did not produce any significant changes in the models. No significant association was found between death and VL in either the unadjusted or the adjusted Cox models.
Progression of VLs. We examined the progression of VLs over time ( figure 1A and 1B) . A model stratified by HTLV type showed that HTLV-I had a statistically significant decrease (Ϫ0.017 log 10 copies/10
6 PBMCs/year; ), but the slope P p .042 of this decrease was minimal and was not likely to be clinically significant. There was no significant change in HTLV-II VLs over time (Ϫ0.019 log 10 copies/10 6 PBMCs/year; ). P p .165 To examine whether any of the baseline demographic or risk factors listed in table 1 were associated with the progression of VLs over time, a stepwise backward-elimination process was used for model specification. The HTLV-I model reduced to a model with race, alcohol, and sex (table 2) . Averaging across all time points (see the main effects for these variables), VLs were significantly higher in men than in women and in alcohol users than in alcohol nonusers. At the longitudinal level (see interactions with time), black persons had a significant negative progression of VL, compared with white persons, and alcohol users had a marginal increase in VL progression, compared with alcohol nonusers. The HTLV-II model reduced to a model that included race, sex, and smoking. Averaging across all time points (see the main effects), there were no significant differences in VLs. In terms of VL progression (see interactions with time), smokers had a marginal increase in VL over time, compared with nonsmokers.
Because complete blood count data were available for almost all subjects at baseline, we examined whether the baseline lymphocyte count could account for changes in VL. At baseline, there was a positive association between smoking and a higher lymphocyte count ( ) but none between lymphocyte P p .022 count and log 10 VL. In the serial VL group, there was a positive time-averaged association between lymphocyte count and log 10 VL ( ). No change in lymphocyte counts was seen over P p .068 time, nor was there an association between lymphocyte count and baseline smoking status. We did not include changes in smoking status in our models; however, among subjects for whom serial VL data were available, 2 started smoking, 9 quit smoking, and 49 did not change their smoking status.
Serial VL and disease outcomes. Unadjusted GEE models were used to examine whether 15 health outcomes had differing progressions of VL in the subset of cohort subjects for whom serial VL data were available (table 3). In the HTLV-I-infected group, only arthritis ( ), bladder infections ( ), bronn p 8 n p 7 chitis ( ), hypertension ( ), and urinary incontinence n p 8 n p 7 or urgency ( ) had enough incident cases for analysis, and, n p 7 in the HTLV-II-infected group, only bladder infection (n p ), bronchitis ( ), and urinary symptoms ( ) could 9 n p 7 n p 7 be analyzed. In the HTLV-I analysis, bladder infection, kidney infection, and the combined bladder/kidney infection variables were associated with the progression of VL. In the HTLV-II analysis, the combined bladder/kidney infection variable was significantly associated with the progression of VL. In other words, subjects with urinary-tract infections had a greater increase in VL over time than did those without such infection. Additionally, unadjusted GEE models were used to examine subjects without any of the 15 health outcomes, to determine whether the progression of their serial VLs differed significantly. In neither the HTLV-I-infected nor HTLV-II-infected subjects did the serial progression of VLs of the disease-free subjects differ significantly.
DISCUSSION
Although HTLV-I has been linked to ATL and both HTLV-I and -II to HAM, little is known about the evolution of HTLV infection in asymptomatic carriers or in those who later develop other disease outcomes. Our results show that, overall, HTLV-I and -II VLs do not increase to a clinically significant degree over time. However race, alcohol use, and smoking were associated with small differences in the progression of VL. Additionally, baseline VLs were not associated with a variety of observed disease outcomes, but a progressive increase in serial VLs was found to be associated with bladder and/or kidney infection-outcomes that may be early symptoms of HAM [18, 19] . Generally, the propagation of HTLV infection is thought to occur through clonal expansion of infected lymphocytes, but only limited prospective data on the time course of HTLV-I VL, and none on that of HTLV-II, have been available. In our model of the progression of VL in HTLV infection, neither HTLV-I nor HTLV-II had an increasing VL over time. Instead, both HTLV-I and -II showed small decreases in VL, but the overall magnitude of the decrease was very small and was not likely to be clinically significant. Manns et al. [13] found high HTLV-I VLs initially in 10 patients that then decreased slightly over the course of the first 36 months after transfusion-related infection. Taylor et al. [15] found HTLV-I VLs to be stable over the course of a mean of 27 months of follow-up in 16 HTLV-I carriers, and there was a trend toward higher VLs in symptomatic than in asymptomatic patients. Okayama et al. [20] found HTLV-I VLs to be stable over the course of several years in 8 seroconverters, most of whom had been infected sexually.
These data suggest that clonal expansion is counterbalanced by factors that limit HTLV VLs. This could occur via the downregulation of the tax-mediated proliferation of infected lymphocytes by the expression of other HTLV genes such as rex or by the viral proteins p30 II and p30 II [5, 21] . Alternatively, lymphocytic proliferation and clonal expansion could proceed vigorously, but an immunologic response to the HTLV-infected cells could kill them as quickly as they proliferate [22] . The recent finding of a high turnover rate of HTLV-I-infected cells has been interpreted as supporting the concept of a balance between clonal expansion balanced by immunologic suppression [23, 24] . Immunologic surveillance could also spur the evolution from multiple small clones to fewer large clones of HTLV-infected lymphocytes [25] .
Despite the overall stability of HTLV VLs over time, we did find associations with race, alcohol use, and smoking history among the 60 subjects with serial VL data. Blacks infected with HTLV-I and Hispanics infected with HTLV-II had more pronounced decreases in VLs. Such associations could potentially be explained by genetic or cultural background, as was suggested in our previous analysis of baseline data [7] . In support of a genetic basis, HLA type has been shown to be a determinant of HTLV-I VLs [26] . Another study involving murine models of HTLV-I infection showed that genetic background could be a determinant of VLs [27] . Alternatively, ethnocentric dietary habits may affect VLs, as has been reported for green tea consumption in Japan [28] . We found a small and only borderline significant, time-dependent increase in HTLV-I VLs in subjects with moderate alcohol consumption. Ethanol consumption has been shown to inhibit NK cell cytolytic activity in mice [29] . Another study found that ethanol consumption by mice caused a rapid decrease in splenic cellularity that was accompanied by a decrease in Th1 function and a rapid increase in systemic IgE levels [30] .
Cigarette smoking was weakly associated with an increase in HTLV-II VLs over time. A potential explanation for this association is the effect of smoking on T lymphocyte counts, known as "smoker's leukocytosis" [6, 31] . We examined the hypothesis that smoking leads to increased lymphocyte counts and, in turn, to increased HTLV VLs. Although this causal pathway could not be supported by the data, we did find an association between baseline smoking and baseline lymphocyte count and, also, an expected association between serial lymphocyte count and serial VLs. Additionally, the effect of smoking on lymphocyte counts has been shown to differ on the basis of race [32] [33] [34] . These observations and the weakness of an association with smoking suggest that there may be additional factors or an interaction between smoking and another variable. Our evaluation of smoking was done at baseline and did not account for subjects who started or quit smoking as the study progressed, because the effect has been found to be reversible [35] . However, our findings are probably conservative, because most subjects who changed their smoking status stopped smoking. We evaluated baseline VLs for any association with several health outcomes. Previous studies have suggested an association between higher HTLV-I VLs and HAM, but these studies examined VLs after the diagnosis of HAM [11, 19, [36] [37] [38] . One study reported no association between prediagnostic VLs and HAM but only examined 9 subjects [39] . Additionally, one study showed an association between increased VL and leukemogenesis and ATL [14] . Although we excluded subjects with HAM or ATL from the present analysis, several of our health outcomes (arthritis, bladder infection, kidney infection, and pneumonia) are considered to be manifestations of HTLV infection or its associated immune response. Using baseline VLs, we were unable to find any association with subsequent health outcomes, which suggests that a single VL measurement is not a good predictor of subsequent disease progression.
However, when we further examined serial VL and health outcomes, we found in both HTLV-I-and HTLV-II-infected subjects that those with bladder or kidney infection tended to have increasing VLs. We have previously proposed that urinarytract symptoms and diagnoses could potentially be the early signs of HAM, because a neurogenic bladder is one of the first manifestations of the myelopathy. These results are suggestive that the progression of VL is potentially diagnostic of HTLVrelated bladder symptoms, which, in turn, could presage more serious HTLV-associated diseases, such as HAM. Associations with other putative HTLV health outcomes (arthritis and pneumonia) were not seen, and there were not enough cases of pneumonia for us to have reliably detected an association.
Our study had several potential limitations. First, although our technique to measure HTLV VLs had good interassay reliability, we are unsure whether small variations in VLs could have been caused by variability of the assay or sample preparation, particularly for the occasional large deviations in VLs observed in the serial data. Because the overall variations in HTLV VLs were small, such variation could have a significant impact on results. Second, we used only baseline data for lymphocyte count and smoking status in our models. Future analyses should be expanded to include such data from all time points. Finally, our power to detect weak associations with serial VLs was hindered by our small sample size and our random, rather than disease-driven, selection of subjects. Thus, the substudy of serial VLs should be viewed as a preliminary analysis, and additional studies of serial HTLV VLs from this and other prospective cohorts could address some of these shortcomings.
In conclusion, the present study has yielded new information about long-term VLs and the natural history of HTLV-I and -II infection. Our primary finding of stable VLs over the course of 10 years is robust and supports the concept of a balance between virus-induced clonal proliferation and the immunologic control of HTLV infection. The secondary finding of increasing HTLV VLs in association with urinary-tract diagnoses needs to be replicated by including more subjects with these and similar diagnoses. Similar large-scale prospective VL studies, which ideally would include an assessment of the clonality of HTLV integration, need to be done with subjects in this and other cohorts who later develop HAM and ATL. Particular attention should be paid to comparative studies of HTLV-I versus -II infection, because both may lead to HAM, but only HTLV-I causes ATL. Until additional studies are completed, it would be premature to propose the serial measurement of HTLV VL as a prognostic marker for HTLV-related disease.
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